Related Experiment Video
Updated: Oct 1, 2026

Achieving Efficient Fragment Screening at XChem Facility at Diamond Light Source
Published on: May 29, 2021
Advancing Drug Discovery through Academia-Industry Collaborations: Lessons from Merck Discovery Chemistry
Beryl X Li1, Dipannita Kalyani2
1Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States.
Abstract:
Academia-industry partnerships are an important driver of innovation in drug discovery, and their success depends on intentional problem selection, effective resource sharing, and robust communication during project execution. This outlook highlights select Merck Sharp & Dohme Discovery Chemistry (MSD DC) collaborations reported over the past five years to illustrate principles that underpin productive academia-industry partnerships. Through representative case studies in synthesis collaborations, we illustrate two complementary collaboration strategies: targeted development of synthetic methods that address key medicinal chemistry bottlenecks, and capability-building efforts that enable technology transfer to accelerate drug discovery. We also highlight a few nonsynthetic collaborations by MSD DC in computational chemistry, structure elucidation, and chemical biology subfields, underscoring the cross-functional impact of these efforts on drug discovery. Beyond scientific advances, these collaborations also provide meaningful training and professional development opportunities for the next generation of chemists.
Related Concept Videos
Drug Discovery: Overview
Preclinical Development: Overview
Clinical Trials: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Production of Pharmaceuticals
Pharmacogenomics: Identification of New Drug Targets
